telmisartan mylan telmisartan 80 mg tablet blister pack
alphapharm pty ltd - telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: meglumine; povidone; sodium hydroxide; magnesium stearate; mannitol - telmisartan mylan is indicated for:,? treatment of hypertension,? prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)
telmisartan mylan telmisartan 40 mg tablet blister pack
alphapharm pty ltd - telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: sodium hydroxide; magnesium stearate; mannitol; povidone; meglumine - telmisartan mylan is indicated for:,? treatment of hypertension,? prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)
tilodene ticlopidine hydrochloride 250mg tablet bottle
alphapharm pty ltd - ticlopidine hydrochloride -
micardis telmisartan 80mg tablet blister pack
boehringer ingelheim pty ltd - telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; sodium hydroxide; sorbitol; meglumine - micardis is indicated for:,?treatment of hypertension in adults,?prevention of cardiovascular morbidity and mortality in adults 55 years or older withcoronary artery disease, peripheral artery disease, previous stroke, transient ischaemicattack or high risk diabetes with evidence of end organ damage (see section 5.1pharmacodynamic properties, clinical trials)
micardis telmisartan 40mg tablet blister pack
boehringer ingelheim pty ltd - telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: sorbitol; sodium hydroxide; povidone; meglumine; magnesium stearate - micardis is indicated for:,?treatment of hypertension in adults,?prevention of cardiovascular morbidity and mortality in adults 55 years or older withcoronary artery disease, peripheral artery disease, previous stroke, transient ischaemicattack or high risk diabetes with evidence of end organ damage (see section 5.1pharmacodynamic properties, clinical trials)
noumed telmisartan telmisartan 80 mg tablet blister pack
avallon pharmaceuticals pty ltd - telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: meglumine; magnesium stearate; lactose; sodium hydroxide; povidone; lactose monohydrate; crospovidone - noumed telmisartan is indicated for: - treatment of hypertension - prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)
noumed telmisartan telmisartan 40 mg tablet blister pack
avallon pharmaceuticals pty ltd - telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: sodium hydroxide; meglumine; lactose; magnesium stearate; povidone; lactose monohydrate; crospovidone - noumed telmisartan is indicated for - treatment of hypertension - prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)
xarelto 20 mg
bayer israel ltd - rivaroxaban micronized - film coated tablets - rivaroxaban micronized 20 mg - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
xarelto 20 mg
bayer israel ltd - rivaroxaban micronized - film coated tablets - rivaroxaban micronized 20 mg - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
pamiray 370 injection
dongkook pharmaceutical co. - iopamidol - solution for injection - 370mg iodine/ml